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Experimental induction of tumours has been widely used to
investigate the anti-tumoural action of agents, which are candi-
dates for therapeutical strategies. Despite some limitations, these
methods offer useful tools, at a preclinical stage, in order to obtain
information on the action mechanism of antineoplastic drugs and
to investigate tumour regression. Transplantation of tumour frag-
ments and isolated cells is currently used; subcutaneous (s.c.)
inoculation of tumour cells in nude mice is the most common and
easy method for growing tumours from human neoplastic cells
(Baselga and Mendelsohn, 1994; Bishop, 1995; Davis et al, 1996;
Perrin et al, 1997). Severe combined immune deficient (SCID)
mice also show tumour cell proliferation. According to Chahinian
et al (1991), xenografts in nude mice are relevant models to inves-
tigate a therapeutical potency in specific tumours. To improve the
relevance of these methods, orthotopic transplantations have been
performed (Astoul et al, 1993; Togo et al, 1995).
Recently, a great deal of interest has focused on human malig-
nant mesothelioma, regarding the severity of the disease, its poor
prognosis (Hoogsteden et al, 1997), and an increasing number of
cases associated with past asbestos exposure and other unknown
reasons, possibly involving SV40 contamination (Carbone et al,
1997). In addition to s.c. implantation, several other models have
been employed including pleural grafts in immunodeficient mice
or rats, and intraperitoneal (i.p.) injection of tumour cells (Astoul
et al, 1993; Smythe et al, 1994; Esandi et al, 1997). However,
tumour implantation through surgery entails inflammatory reac-
tions, scarring and local fibrosis that may interfere with tumour
evolution. Despite its interest regarding similarities between the
pleural and peritoneal environment, the intraperitoneal site is not
the most appropriate for growing mesothelioma cells because peri-
toneal mesothelioma is less frequent than pleural mesothelioma in
humans. It is therefore interesting to develop models as close as
possible to the human situation in order to mimic the human
disease and to follow up both tumour growth and regression when
the models have to be used for therapeutic investigations. This
latter approach requires suitable methods to determine the clinical
status of the animals in order to assess the efficiency of the treat-
ment without sacrifice.
To address these issues we developed a non-aggressive method
for orthotopic transplantation of rat mesothelioma cells in
syngenic and nude rats, and human mesothelioma cells in nude
rats, and followed the post-transplantation clinical evolution.
We demonstrate that tumour evolution can be evaluated by chest
X-ray and body weight.
MATERIALS AND METHODS
Mesothelioma cells
Rat mesothelioma cells were grown from pleural mesothe-
lioma developed in Fischer 344 rats following the intrapleural
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inoculation of 20 mg of crocidolite fibres. The protocols for fibre
inoculation, rat housing and survey, and tumour harvesting have
been described elsewhere (Jaurand et al, 1987). Crocidolite fibres
were provided by the Union Internationale Contre le Cancer. After
tumour excision, mesothelioma cells were cultured according
to standard conditions in RPMI-1640 (Gibco BRL, Life
Technologies, Cergy Pontoise, France) supplemented with 8%
fetal bovine serum (FBS; Biological Industries, ATGC, Noisy le
Grand, France), penicillin and streptomycin, both from Gibco
BRL as described elsewhere (Fleury-Feith et al, 1989). After
several passages to obtain a sufficient number of cells, these were
frozen in complete RPMI-1640 containing 10% dimethyl
sulphoxide (Sigma, Saint Quentin Fallavier, France) and stored in
liquid nitrogen. The mesothelial origin of the cells was confirmed
by the co-expression of keratin and vimentin using an alkaline
phosphatase anti-alkaline phosphatase (APAAP) method (Zeng
et al, 1994). The antibodies used were polyclonal rabbit antibodies
directed against human 56-kDa cytokeratin and monoclonal
mouse anti-swine vimentin 57-kDa, both obtained from DAKO
(78196 Trappes, France).
A human mesothelioma cell line (DEVy) established in our
laboratory was also investigated. This cell line exhibited an
epithelial morphology and co-expressed keratin and vimentin as
previously described (Zeng et al, 1994). In a preliminary study, we
found that DEVy formed tumours in nude mice 1 week after the
s.c. inoculation of 3 ´ 106 cells (unpublished data).
Cell transplantation method
Two sorts of rats were investigated: Fischer 344 IOPS rats,
5 weeks old were obtained from Iffa Credo (L’Arbresle, France)
and nude rats (HsdHan: NZNU-nu, 4–6 weeks old, from Harlan,
France). Procedures for housing and handling of animals were in
agreement with the European Decret (19 October 1987). The
animals were housed for at least 1 week prior to mesothelioma cell
inoculation. Rats were anaesthetized by the intramuscular (i.m.)
inoculation of a mixture composed of 5 mg kg–1 xylazine (ND
Rompun 2%) (Bayer Pharma, Puteaux, France) and 40 mg kg–1 of
Ketamin (ND Imalgene, Rhône Mérieux, Lyon, France). The
method used to permit orthotopic growth of mesothelioma cells
consisted in the deposition in the pleural cavity of a cell suspen-
sion derived from the procedure developed to inject asbestos fibres
in the pleural cavity (Monchaux et al, 1981). The desired amount
of mesothelioma cells was suspended in 0.3 ml of phosphate-
buffered saline (PBS) and sucked into a 1 ml syringe, then fitted to
a 0.8 mm diameter needle. The administration was made on the
right side in the middle of the thorax, between the 6th and 7th ribs.
In a first series of assays, 0.4 ml of a contrast solution (Telebrix 35,
350 mg I ml–1; Guerbet, Aulnay sous Bois, France) diluted 3:4 in
physiological saline or mesothelioma cells mixed with a contrast
solution were administered in order to check the location of the
suspension. Chest X-ray radiographs confirmed the intrapleural
administration of the solution without lung damage as illustrated
in Figure 1.
Experimental protocol
Rat mesothelioma cells were inoculated in three groups of six
Fischer 344 rats treated with 5 ´ 106 (group I), 3 ´ 106 (group II) or
1 ´ 106 (group III) rat mesothelioma cells, according to the proce-
dure described above, without contrast solution. This procedure
allowed the determination of the effect of cell concentration and
the convenient amount for inoculation in nude rats. Consequently,
11 nude rats were further inoculated with 3 ´ 106 rat mesothelioma
cells under the same conditions as Fischer 344 rats. In this latter
experiment, four sham nude rats received 0.3 ml of PBS. The
human mesothelioma cells, DEVy, were inoculated in three nude
rats according to the same procedure.
The animal body weight was controlled every week and chest
radiographs (Konica Medical Films, MG-SR super rapid) were
performed approximately every 10 days, from the second week
after treatment. For this purpose, rats were anaesthetized
according to the procedure described above. Both face and profile
radiographs were made, with a SEDETAL (APR-VET.FL.VET
Veterinary Systems H.F. series generator) apparatus under the
following conditions: 100 mA, 48 kv, 0.01 s.
The animal’s death was either spontaneous or due to a decision
of euthanasia because of body weight loss. Autopsies were carried
out on all subjects. Radiograph interpretations were made blindly
before autopsies. A score from 0 to 3 was attributed to the radio-
graphs, depending on the extent of the chest X-ray abnormalities
based on mediastinum widening, loss of cardiac silhouette with
subcardiac clear space filling and mass deformity of the
diaphragm area. A semi-quantification was made in order to
perform further therapeutical treatments at different stages of
tumour development. The following classifications were made: no
abnormality (score 0); localized abnormalities with small tumour
volume (score 1); diffuse abnormalities or medium tumour
volume (score 2); and large abnormalities with large tumour
volume (score 3).
The tumours were fixed in 10% formal in for anatomo-patho-
logical examination or in glutaraldehyde in cacodylate buffer for
electron microscopy studies, according to standard procedures
(Fleury-Feith et al, 1989). Immunohistochemistry of tumours was
performed to investigate keratin expression. Tumours formed after
the inoculation of rat mesothelioma cells were incubated with
rabbit polyclonal antibodies raised against bovine keratin using
monoclonal mouse anti rabbit IgG as secondary antibodies. Both
Figure 1 Chest radiograph from a Fischer 344 rat immediately after
intrapleural administration of rat mesothelioma cells suspended in PBS
supplemented with contrast liquid solution. This solution diffuses in all the
pleural cavity mainly in the posterior slope space. The cardiac opacity is
outlined by the solution1346 F Le Pimpec-Barthes et al
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agents were obtained from DAKO (Trappes, France). The
revelation was made with a DAKO LABS® (labelled strepta-
vidin–biotin) kit labelled with alkaline phosphatase. Vimentin
expression was determined with a DAKO clone V9
antibodies followed by a peroxidase revelation.
Statistical analyses
Analysis of variance (ANOVA) analyses and t-tests were
performed for weight and chest X-rays score comparisons
(GraphPad PRISM® software, V 2.0 for Macintosh).
RESULTS
Characterization of the rat mesothelioma cell line
We first investigated the phenotype of the cells cultured from
asbestos-induced pleural tumours in Fischer 344 rats used for
transplantation in the present study. This cell line exhibited a
fusiform phenotype but coexpressed keratin and vimentin. Figure
2 shows the morphology and antigenic characterization.
Clinical studies
Figure 3A reports the mean weight of Fischer 344 rats in the
different groups. In all groups, the mean body weight increased up
to about 3 weeks after intrapleural administration of tumour cells.
This increase was normal since these rats continued to gain weight
linearly up to 10 weeks. Thereafter their weight continued to
increase slowly. In the treated animals, a stabilization in weight
rise was observed after 3 weeks in groups III, indicating some
A
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Figure 2 Micrograph of culture of rat mesothelioma cells obtained from an
asbestos-induced rat pleural mesothelioma. Immunostaining with antibodies
directed against (A) cytokeratin and (B) vimentin; (C) control without primary
antibodies (original magnification ´ 100).
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Figure 3 (A) Kinetics of body weight of Fischer 344 rats inoculated with rat
pleural mesothelioma cells: Group I (–l l–); Group II (– –n– –); Group III
(–l–).(B) Chest X-ray scores (mean ± s.e.m.), 15 days (n) and 30 days (n)
after inoculation with mesothelioma cellsRat model for malignant mesothelioma 1347
British Journal of Cancer (1999) 81(8), 1344–1350 © Cancer Research Campaign 1999
metabolic disturbances. Thereafter, a weight loss was evident in
groups I and II, occurring between 24 and 31 days after inocula-
tion. No obvious decrease was observed in the rats belonging to
group III. Statistical analyses showed significant body weight was
found in two group (P < 10–4, ANOVA). Moreover, a significant
decrease in body weight was found in two groups: a significant
lowering in body weight was detected between 24 and 31 days in
group II (paired t-test: P = 0.044) and in group I (P = 0.015); no
significant change was observed in group III (P = 0.73).
In order to determine whether the response of nude rats differed
from that observed in immunocompetent animals, we inoculated
nude rats with the same cell line, under similar conditions with
3 ´ 106 cells. Figure 4A reports the body weight evolution of nude
rats. All rats continued to gain weight until 13 days after treatment,
but the body weight of rats inoculated with mesothelioma cells
was reduced after 3 weeks post-inoculation. Significant time-
dependent body weight changes were found in both sham and
treated rats (P < 10–4 ANOVA). The body weight of sham animals
continued to rise between 20 and 33 days post-inoculation (paired
t-test: P = 0.006). In contrast, the body weight of treated animals
decreased at the same time (paired t-test: P = 0.0096). However,
the differences in body weight in mesothelioma cells versus sham-
treated animals was not statistically significant. Despite the
limited number of nude rats inoculated with the human mesothe-
lioma cell line, similar conclusions can be drawn. A reduction in
body weight of 7% to 3%, depending on the animal, was observed
20 days after inoculation (data not shown).
Chest X-ray analyses
Figure 5 illustrates the radiographical abnormalities encountered
in treated animals. They consisted in pleural effusion, widening of
the mediastinal opacity and more or less filling of clear space
under cardiac opacity. Table 1 reports the radiographic scores
attributed 15 and 30 days following intrapleural administration of
the rat pleural mesothelioma cell line in Fischer 344 rats. In no
group were important abnormalities detected 15 days after inocu-
lation of rat mesothelioma cells, but differences among the three
groups appeared later. The mean scores were 0.25, 0 and 0.5 in
groups III, II and I, repectively, after 15 days; they reached 1.2,
2.25 and 2.5 after 30 days (Figure 3B). There was a significant
enhancement in chest X-ray scores between 15 and 30 days in
groups II and I (P = 0.005 and 0.0012 respectively, t-test) but not
in group III for a = 5% (P = 0.051). Features suggesting massive
tumour volumes were observed in all rats from group I and in most
of the rats in group II 30 days after inoculation. In these groups,
tumour progression was observed in the surviving rats, on chest
X-rays performed 43 days after inoculation since all scores
reached 3. The tumour progression, as assessed by chest X-ray
analysis, was also observed in rats from group III at the end of the
experiment (day 43) but the radiographic changes were more
limited after 30 days, in comparison with the other groups since
the mean value was lower than 2 (Figure 3B) and no individual
score reached 3.
Table 2 reports the chest X-ray analyses in nude rats inoculated
with rat mesothelioma cells 10, 22 and 29 days after inoculation.
Chest X-ray abnormalities were detected 22 days after inoculation
in seven out of 11 rats inoculated with the rat mesothelioma cells.
After a delay of 29 days, scores were higher than, or equal to,
1 in every rat while normal chest X-rays were observed in sham
animals. Scores were significantly enhanced between 10 and
22 days after inoculation (P = 0.0023).
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Figure 4 (A) Kinetics of body weight of nude rats inoculated with rat pleural
mesothelioma cells: Sham-treated (–l l–); treated with mesothelioma cells
(–n–). (B) Chest X-ray scores in rats inoculated with mesothelioma cells (n);
mean ± s.e.m.
A B
C D
Figure 5 Chest X-ray films showing: normal chest X-rays (A); pleural
effusion in all the cavity (B); widening of the mediastinal opacity (C); filling
clear space under cardiac opacity (D)1348 F Le Pimpec-Barthes et al
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Pathological findings
Gross findings
Autopsies were performed in three Fischer 344 rats after sponta-
neous death, and after euthanasia decided on the basis of body
weight loss and chest X-ray abnormalities in the remaining
animals. All rats exhibited massive tumours predominantly
invading the mediastinum and pericardium and involving the
diaphragm (Figure 6). An extension to the lungs was occasionally
found. Tumour metastases were not found in the visceral organs.
Similar aspects were observed with human cells and rat cells.
Anatomo-pathology of tumours
Pleural tumours that developed after implantation of rat mesothe-
lioma cells in Fischer 344 rats were examined according to routine
protocols. The semi-thin sections demonstrated a fusiform tumour
phenotype with infiltration of mastocytes and in some cases
tumour invasion in adjacent tissues. A few lymphocytes infiltrated
the tumour. According to ultrastructural analysis, a proliferation of
cells rich in ribosomes and rough endoplasmic reticulum was
detected. In some cases the presence of desmosomes provided a
clue for epithelial differentiation of the cells. Immuno-histo-
chemistry analysis demonstrated the expression of keratin and
vimentin in the tumour cells (Figure 7). Similar features were
found in Fischer 344 rats and in nude rats. Tumours formed in
nude rats inoculated with the human mesothelioma cell line were
consistent with epithelial malignant mesothelioma.
DISCUSSION
The data reported in this study have demonstrated that orthotopic
mesothelioma growth can be obtained by a careful administration
of tumour cells within the pleural space in anaesthetized rats,
without surgical trauma. In addition, we found that chest X-ray
analysis can be carried out to detect pleural tumours. To our
knowledge, this is the first report on a systematic investigation of
clinical survey and tumour evolution in rats.
As far as pleural and lung tumours are concerned, tumour trans-
plantation has generally been carried out by s.c. injection of
neoplastic cells in immunodeficient mice, or to perfect a more
relevant model of mesothelioma, in the peritoneal cavity of mice
(Smythe et al, 1994; Hwang et al, 1995). More recently, orthotopic
implantation by injection via thoracotomy (Astoul et al, 1993;
Esandi et al, 1997) has been developed providing a relevant model
of pleural mesothelioma. However, thoracotomy is invariably
associated with trauma to the pleural cells and subpleural tissue
then followed by processes of inflammation and tissue repair. The
production of inflammatory molecules and growth factors may
interact with neoplastic cell proliferation and graft. In the present
study the use of delicate transthoracic inoculation will minimize
Table 1 Chest X-ray analysis of Fischer 344 rats after intrapleural
administration of a rat pleural mesothelioma cell line
Delay after inoculation
(days)
Group Rat no. 15 30
I 1 0–1 3
20 2
30 3
40 3
5N D2
6N D2
II 7 0 3
80 3
90 1
10 0 3
11 ND 3
12 ND 0–1
III 13 0 0–1
14 1 2
15 0 1
16 0 1
17 ND 2
18 ND 0–1
ND: not done.
Table 2 Chest X-ray analysis of nude rats after intrapleural administration of
a rat pleural mesothelioma cell line*
Delay after inoculation (days)
Group Rat no. 10 22 29
Treated 1a 0 0 1–2
1 b023 a
2 a00 2
2 b02 3
2 c00 1
3 c00 1
4 a01 2
4b 0–1 2 3
501 2
6 0 1–2 2
7013 a
Sham 3a 0 0 0
3 b00 0
800 0
900 0
aPleural fluid at autopsy.
Figure 6 Autopsy from a nude rat inoculated with rat mesothelioma cells.
Gross examination showing nodules are at different locations on the parietal
pleura, under cardiac space and on the cardiac pleuraRat model for malignant mesothelioma 1349
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these reactions (Gutman and Fidler, 1995). A pitfall of this method
could occur in the damage to lung parenchyma and/or creation of
pneumothorax due to needle injury. However, these problems were
never encountered in our experiments.
The data reported here have demonstrated that cells isolated
from pleural malignant mesothelioma produced in Fischer 344
rats following inoculation of asbestos fibres can be successfully
transplanted in both syngenic and nude rats, and that human
mesothelioma cells formed malignant mesothelioma when
xenografted in nude rats. There was a clear-cut dose–response
effect when several concentrations of cells were inoculated. Chest
X-ray analyses confirmed the occurrence of the disease and
permitted the detection of pulmonary and pleural abnormalities in
correlation with the clinical status. The body weight curves appear
to be a good clinical parameter to detect mesothelioma growth. In
Fischer 344 rats a weight loss was associated with a rapid progres-
sion of the disease, as assessed by chest X-ray analysis and
confirmed by autopsies.
Autopsies in Fischer rats that died spontaneously have shown
that the tumour grew in the pleural cavity and diffused to the lung,
but no metastases were found despite a massive invasion of the
lung in later stages. Therefore, animal death was clearly associated
with the respiratory malignancy. The features are similar to those
found in the human situation (Corson, 1986). Similar patterns
were observed in both euthanased Fischer 344 and nude rats
inoculated with rat mesothelioma cells.
Mesotheliomas formed after the inoculation of the human
mesothelioma cells were less invasive, but nodules were found at
the same place as in syngenic rats. In addition, some adherence
between the diaphragm and liver was detected in nude rats inocu-
lated with human mesothelioma cells.
Tumour histology was in agreement with the cytological find-
ings exhibited by the cultured cells, that is poorly differentiated
tumours composed of fusiform cells co-expressing keratin and
vimentin in the case of mesothelioma resulting from the inocula-
tion of rat cells, and epithelial mesothelioma after inoculation of
the human mesothelioma cells. It may be emphasized that the
histological features of the tumours were similar in every animal,
independently of the rat strain and of the stage of the disease. This
reproducibility suggests that large groups of animals should not
be necessary for experimental trials.
It was also found that rat mesothelioma cell transplantation in
Fischer 344 rats resulted in faster tumour growth in comparison
with that of nude rats. Thirty days after inoculation, two out of
three chest X-ray films in Fischer 344 rats reached a score of 3,
while only 37% of the nude rats reached that score at the same
period. However, gross pathological findings and morphological
features of resulting tumours were similar in both sorts of rats,
indicating that nude rats develop tumours similar to those formed
in immunocompetent rats. This observation is very important
regarding the need to use immunodeficient rats for transplantation
of human cells. We can therefore suggest that the pathological
features of tumours formed in nude rats will have some relevance
to human pathology.
Nowadays, it is important to have accurate models to test new
therapeutical approaches and understand the action mechanism of
drugs at the cellular and molecular level, especially regarding the
development of new strategies, including gene transfer in tumours
as recently recommended by the National Institutes of Health
(Ross et al, 1996). Animal models are therefore necessary to
achieve this goal. The model developed here will be useful to
investigate mesothelioma proliferation and the effects of drugs and
new strategies of interest for mesothelioma therapy. Our studies
also demonstrated that the clinical survey of rats is possible. This
is an important finding because it will permit both the follow-up
of tumour evolution and regression whilst keeping the animal alive
and the observation of a recurrence of the disease. Sterman
et al (1993) recently reported results of a phase I clinical trial
using adenovirus-mediated herpes simplex virus thymidine
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Figure 7 Typical histological section of a tumour found in Fischer 344 rats
inoculated with rat mesothelioma cells. (A) Hematoxylin and eosin stain;
immunostaining with antibodies directed against (B) vimentin, (C) keratin
(original magnification ´ 400)1350 F Le Pimpec-Barthes et al
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kinase/ganciclovir gene therapy in malignant mesothelioma. The
authors demonstrated that improvement of these methods is neces-
sary for a better transfer of the vector in the tumours. The use of
animal models is therefore of paramount importance to investigate
the extent and depth of the virus in the tumour. The present exper-
iments have demonstrated that gentle administration of meso-
thelioma cells in the rat pleural cavity and clinical survey are
relevant and useful tools for malignant mesothelioma investigation
in immunocompetent as well as in immunodeficent rats.
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